Company news

BioCryst Pharmaceuticals, Inc. news in 2020

BioCryst Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.

View company

BioCryst Provides Update on Galidesivir Program

December 21, 2020

BioCryst Announces Positive Phase 1 Results with BCX9250, an Oral ALK-2 Inhibitor for Treatment of Fibrodysplasia Ossificans Progressiva

December 20, 2020

BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema

December 15, 2020

BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management

December 6, 2020

BioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement

December 5, 2020

BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients

December 2, 2020

BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones

November 4, 2020

BioCryst’s Oral Factor D Inhibitor, BCX9930, Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naïve PNH Patients

September 29, 2020

U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile

September 2, 2020

NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir

August 30, 2020

BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones

August 5, 2020

BioCryst to Report Second Quarter 2020 Financial Results on August 6

July 22, 2020

BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States

June 8, 2020

BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock and Pre-Funded Warrants

May 31, 2020

BioCryst Prices Public Offering of Common Stock and Pre-Funded Warrants

May 26, 2020

BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones

May 5, 2020

BioCryst to Report First Quarter 2020 Financial Results on May 6

April 21, 2020

BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19

April 8, 2020

BioCryst Appoints Anthony Doyle Chief Financial Officer

April 1, 2020

BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930

March 4, 2020

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

March 1, 2020

BioCryst Appoints Alan G. Levin to Board of Directors

February 24, 2020

BioCryst to Report Fourth Quarter and Full Year 2019 Financial Results on March 5

February 19, 2020

FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks

February 17, 2020

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 5, 2020

BioCryst Submits Japanese New Drug Application for Oral, Once Daily Berotralstat

February 2, 2020

BioCryst Strengthens Commercial Rare Disease Leadership

January 14, 2020

BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

January 5, 2020

Calls in 2020

Decks in 2020